...
首页> 外文期刊>International Journal of Nanomedicine >Folic acid-tethered Pep-1 peptide-conjugated liposomal nanocarrier for enhanced intracellular drug delivery to cancer cells: conformational characterization and in vitro cellular uptake evaluation
【24h】

Folic acid-tethered Pep-1 peptide-conjugated liposomal nanocarrier for enhanced intracellular drug delivery to cancer cells: conformational characterization and in vitro cellular uptake evaluation

机译:用于增强细胞内药物输送到癌细胞的叶酸 - 系酸肽肽 - 肽 - 缀合的脂质体纳米载体:构象表征和体外细胞摄取评价

获取原文
           

摘要

Background: A novel dual ligand–modified liposome, folic acid-tethered Pep-1 peptide-conjugated liposomal nanocarrier (FP-Lipo), was designed to overcome the nonselectivity of conventional penetrating peptide-tagged nanoparticulates and to provide the advantage of selective targeting of the folic acid receptor, which is frequently overexpressed on epithelial cancer cells. Methods: FP-Lipo was prepared by a sequential process of formation of a maleimide-derivatized small unilamellar vesicle, postinsertion of distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000–folate to the vesicle, and Pep-1 peptide conjugation via thiol-maleimide linkage. Conformational and physical characteristics of the FP-Lipo nanocarriers were investigated for the extent of Pep-1 peptide and folic acid on the surface, vesicle size, and zeta potential. In vitro cellular uptake behaviors of the novel carrier containing a fluorescein dextran isothiocyanate probe were examined by spectrophotometry or by confocal laser scanning microscopy. Results: A novel nanocarrier bearing approximately 750 folate ligands and 100 penetrating peptides per vesicle was successfully prepared. The physical properties were as follows: 140 nm in size; 5 mV in zeta potential; less than 0.3 in polydispersity index. An in vitro cellular uptake study revealed that the FP-Lipo nanocarrier system exhibited more than twofold enhanced translocation into the folic acid receptor–positive HeLa cells compared with the single Pep-1 peptide–modified liposome. Meanwhile, its cellular association and internalization into the folic acid receptor–negative normal HaCaT cells was comparable with that of Pep-1 peptide–modified liposome. Conclusion: An advanced dual ligand-modified liposome is potentially useful for the treatment of folic acid receptor–positive tumors with high translocation capability of the penetrating peptide–modified liposome.
机译:背景:设计一种新型双配体改性脂质体,叶酸 - 系膜肽肽缀合的脂质体纳米载体(FP-LIPO),旨在克服常规穿透肽标记的纳米颗粒的非必需性,并提供选择性靶向的优点叶酸受体经常在上皮癌细胞上过度抑制。方法:通过硫醇 - 马来酰亚胺键合的马来酰亚胺衍生的小单层囊泡,将Distearoyl磷脂酰乙醇胺 - 聚乙二醇和PeP-1肽缀合的蛋白酰亚胺乙酰乙醇胺 - 聚乙二醇二甲醇2000-叶片的开发期制备FP-Lipo。研究了FP-Lipo纳米载体的构象和物理特征,用于Pep-1肽和叶酸在表面,囊泡尺寸和Zeta电位上的程度。通过分光光度法或通过共聚焦激光扫描显微镜检查含有荧光素葡聚糖异硫氰酸酯探针的新型载体的体外细胞摄取行为。结果:成功制备了一种新型纳米载体,其轴承约750叶酸配体和100个渗透肽。物理性质如下:140nm的尺寸; Zeta潜力5 mV;多分散指数小于0.3。在体外细胞摄取研究表明,与单百分比肽改性的脂质体相比,FP-Lipo纳米载体系统表现出叶酸受体阳性HeLa细胞中的大于双重增强的易位。同时,其细胞结合和内化进入叶酸受体 - 阴性正常HaCAT细胞的细胞与Pep-1肽改性脂质体的相当。结论:晚期双配体改性脂质体潜在可用于治疗渗透肽改性脂质体的高易位能力的叶酸受体阳性肿瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号